Solar Kitties | Energy & Longevity
Exploring alt-energy, longevity, biotech, and emerging markets through witty and rigorous independent, non-bias investment research.
- Top in Finance
- #29
- Paid subscribers
- 10+ paid
- Followers
- 106K
- Paid plan
- $9.99/mo
- Recommends
- 3
- Podcast
- Yes
other newsletters
What they write about
Independent research on biotech, longevity and energy infrastructure. Recurring subjects include medical devices and bioelectronic medicine, cancer and gene-editing therapeutics, FDA regulatory pathways, small-cap biotech consolidation, and high-voltage transmission and subsea grid projects.
- biotech
- longevity
- medical devices
- gene editing
- energy infrastructure
- small caps
Recent examples: The Night Shift: How Firm Solar Challenges Nuclear’s Reliability Premium · The Night Shift: How Firm Solar Challenges Nuclear’s Reliability Premium
Written from Solar Kitties | Energy & Longevity’s own published post titles and openings in Sep 11, 2026. It describes the subjects the newsletter covers, not its views, and is not investment advice.
Growth history
Subscribers (thousands, nightly)
52K on Sep 10, 2026 → 108K on Oct 21, 2026
Followers (thousands, nightly)
Rank in Substack’s finance leaderboard: #29 today · #307 a week ago · #22 a month ago
Stats worth sharing
Tracked since Sep 10, 2026 — 59 daily snapshots so far. The card below is built from what we track and refreshes nightly.
- Percentile
- Top 6%
- Best rank seen
- #19
- Rank, 7 days
- +278 places
- Rank, 30 days
- −7 places
- Followers added
- +54K
- Posts
- 4
- Reactions per post
- 20
- Reactions tracked
- 394
of 525 ranked finance newsletters
on Sep 28, 2026
since tracking began
last 30 days
average, recent posts
across 20 posts
Most-reacted post we have seen: The Subsea Grid & The Transcontinental Power Arbitrage — 42 reactions on Aug 11, 2026.
Recent posts
- The Night Shift: How Firm Solar Challenges Nuclear’s Reliability Premium
Solar Kitties Research / Energy & Infrastructure / November 4, 2026 By C.D. Lawrence, Solar Kitties Research | November 4, 2026 Cheap solar and dependable delivery are different products. The next power-system contest is about combining them—not crossing nuclear off the map. TL;DR: The Solar Kitties Framework The Problem: Investors keep comparing the cost of a sunny-hour megawatt-hour with the cost of dependable electricity, as though both come with the same warranty. The Solution: Separate energy production, daily time-shifting and all-weather reliability, then identify who can sell each…
- The Night Shift: How Firm Solar Challenges Nuclear’s Reliability Premium
Solar Kitties Research / Energy & Infrastructure / November 4, 2026 By C.D. Lawrence, Solar Kitties Research | November 4, 2026 Cheap solar and dependable delivery are different products. The next power-system contest is about combining them—not crossing nuclear off the map. TL;DR: The Solar Kitties Framework The Problem: Investors keep comparing the cost of a sunny-hour megawatt-hour with the cost of dependable electricity, as though both come with the same warranty. The Solution: Separate energy production, daily time-shifting and all-weather reliability, then identify who can sell each…
- The Night Shift: How Firm Solar Challenges Nuclear’s Reliability Premium
Solar Kitties Research / Energy & Infrastructure / November 4, 2026 By C.D. Lawrence, Solar Kitties Research | November 4, 2026 Cheap solar and dependable delivery are different products. The next power-system contest is about combining them—not crossing nuclear off the map. TL;DR: The Solar Kitties Framework The Problem: Investors keep comparing the cost of a sunny-hour megawatt-hour with the cost of dependable electricity, as though both come with the same warranty. The Solution: Separate energy production, daily time-shifting and all-weather reliability, then identify who can sell each…
- The Blood-Test Tollbooth: Why Payer Coverage, Not Scientific Promise, Will Decide Multi-Cancer Screening
Solar Kitties Research / Longevity & Biotech By C.D. Lawrence, Solar Kitties Research | November 1, 2026 The blood draw is the easy part. The commercial tollbooth sits between a molecular signal and a funded, resolved care pathway. The thesis in sixty seconds TL;DR: The Solar Kitties Framework The Problem: Multi-cancer early detection, or MCED, can identify cancer-associated signals in blood, but a positive result starts a diagnostic pathway rather than ending one. The test may be additive to existing screening, not a replacement. The Solution: Treat MCED as a coverage-and-pathway business…
- Genflow Biosciences (GENFF): The Gene That Learned to Age Slowly
TL;DR New catalyst: Genflow says the randomized, blinded SLAB study met its primary endpoint , a reduction in biological age measured with the GRIM methylation clock . Detailed results are scheduled for the Animal Longevity Summit on October 2 , 2026. [ 1 ] What exists: 24 aged beagles in four arms: two naked plasmid-DNA dose groups, one AAV8 group, and a saline control. The dog product and the human lead use different delivery approaches. [ 1 ][ 2 ] What does not exist: published full canine endpoint tables, peer-reviewed evidence of canine lifespan extension, or a clinical demonstration…
- The Blood-Test Tollbooth: Why Payer Coverage, Not Scientific Promise, Will Decide Multi-Cancer Screening...
TL;DR The Problem Medicine routinely screens for only a handful of cancers. Multi-cancer early detection, or MCED , promises to search one blood sample for molecular signals from dozens more. But a screening result is not a diagnosis. Every positive can trigger imaging, specialist visits, biopsies and weeks of uncertainty—and payers must decide whether the entire chain improves health enough to justify its cost. The Solution MCED tests analyze fragments and chemical patterns shed into the bloodstream, then use algorithms to estimate whether cancer is present and where the signal may have…
- The Humanoid Gold Rush Has a Laundry Problem: 20 Million Robots Sold. Just 536 Could Care for You...
TL;DR The Problem The home is the most valuable—and least forgiving—worksite left to automate. It is cluttered, constantly changing, full of fragile objects, pets, children, stairs, private conversations and humans who do not behave like factory fixtures. A machine that is impressive on a stage can still be commercially useless if it breaks a wineglass, frightens a parent or needs a remote operator every time a sock disappears beneath a bed. The Solution Humanoid robots will not win the home by arriving as flawless mechanical butlers. They will enter through a wedge : one narrow, frequent and…
- The Trip Switch: How Non-Hallucinogenic Neuroplastogens Could Rewire Psychiatry—and Its Economics
TL;DR: The Solar Kitties Framework The Problem: Depression and related brain disorders are often treated with drugs that require chronic dosing, take weeks to work, and fail a meaningful share of patients; psychedelic therapies may act faster, but their acute psychoactive effects turn treatment into an expensive supervised event. The Solution: Non-hallucinogenic neuroplastogens are engineered to promote rapid structural and functional plasticity without producing a psychedelic experience—potentially converting a clinic-bound therapy into a conventional prescription medicine. The Opportunity…
- Why Bioelectronic Medicine Wins, One Indication at a Time...
Solar Kitties Research | Bioelectronic Medicine & Medical Devices The article’s clinical, operating, and regulatory milestones are indication-specific. The investable question is whether a device can turn a biological effect into a safe, reimbursed, repeatable treatment. TL;DR — The Solar Kitties Framework Problem - “Bioelectronic medicine” bundles together implanted stimulators, wearables, vagus-nerve therapies, spinal-cord systems, and laboratory interfaces. That makes for a handsome pitch deck—and a lousy investment category. Solution - Treat each program as an indication-specific…
- The IOU in the Gucci Blazer: What Tokenized Stocks Actually Own...
TL;DR -- The Solar Kitties Framework Problem “Tokenized stocks” are not one instrument. A wallet balance can represent registered ownership, a security entitlement, a synthetic linked product, or a contractual claim on an intermediary. Treating them as interchangeable is how investors buy the plumbing diagram instead of the plumbing. Solution The winning stack links a digital record to the official securityholder file, identity checks, transfer restrictions, corporate actions, custody, and delivery-versus-payment. The ledger is useful. The legal and operational control plane is indispensable…
- The Peripheral Rebellion: Why Parkinson’s Drug Discovery Is Moving Below the Neck
Solar Kitties Research | Parkinson’s, Microbiome & Precision Biotech In some patients, the actionable biology may begin far from the substantia nigra. The opportunity is not a miracle probiotic. It is a precision stack that can identify risk, control microbial chemistry, and finally tell researchers which patients might respond before they spend a decade—and a small country’s GDP—on the wrong trial. TL;DR: The Solar Kitties Framework The Problem: Parkinson’s is expanding faster than the old brain-only drug-development playbook can produce disease-modifying therapies, while biological…
- Merck’s Cancer Vaccine Is Only the Beginning - The Next Cancer Winner May Not Make Vaccines...
TL;DR — The Interception Thesis Problem: Cancer care still spends its largest checks after a tumor recurs, when the biology is hardest to control and the patient’s options are narrowest. Solution: Sequencing, circulating tumor DNA (ctDNA), individualized neoantigen design, therapeutic vaccination, checkpoint blockade, and RAS-targeted drugs are starting to operate as one precision loop. Opportunity: Merck and Moderna’s positive Phase 3 melanoma result validates the vaccine layer. Guardant validates the surveillance layer. Revolution Medicines validates the molecular-attack layer. The…
← All trending finance newsletters
Data: Substack public leaderboards and publication archives, refreshed nightly, plus public beehiiv sitemaps and recommendation pages, refreshed weekly. Source for this page: Solar Kitties | Energy & Longevity. Subscriber counts are Substack’s own rounded public figures, so week-on-week changes move in steps. beehiiv audience sizes are self-reported by the publisher and are not verified. Last snapshot: Nov 10, 2026.